Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Entos Pharmaceuticals Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are both located within 1 distinct art unit, suggesting a very specific technical focus for the company's current pharmaceutical filings. Concentration in 1 art unit can lead to a more consistent examination process as the company deals with a single set of technical reviewers.
The prosecution is handled by 1 distinct examiner, LEONARD, ARTHUR S. As the busiest examiner for the portfolio, LEONARD, ARTHUR S is responsible for 2 pending office actions. This represents the entirety of the company's current pending workload, centralizing all USPTO communications with a single individual. This centralization can be beneficial for maintaining a unified narrative across multiple applications.
For the legal team, having 2 pending office actions managed by 1 distinct examiner in 1 distinct art unit indicates a highly focused prosecution environment. The strategy for this Biotechnology & Pharmaceuticals portfolio should be heavily informed by the specific preferences and past decisions of LEONARD, ARTHUR S. This streamlined structure reduces the administrative complexity of managing multiple examiner relationships while focusing efforts on a single point of contact.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEONARD, ARTHUR S | 2 | 50.8% | +50.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029823 | PROTEOLIPID VESICLES FORMULATED WITH FUSION ASSOCIATED SMALL TRANSMEMBRANE PROTEINS | LEONARD, ARTHUR S | 62d |
| 18613605 | PROTEOLIPID VESICLES FORMULATED WITH FUSION ASSOCIATED SMALL TRANSMEMBRANE PROTEINS | LEONARD, ARTHUR S | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18613605 | PROTEOLIPID VESICLES FORMULATED WITH FUSION ASSOCIATED SMALL TRANSMEMBRANE PROTEINS | LEONARD, ARTHUR S | 1631 | §103 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18029823 | PROTEOLIPID VESICLES FORMULATED WITH FUSION ASSOCIATED SMALL TRANSMEMBRANE PROTEINS | LEONARD, ARTHUR S | 1631 | §103§112DPOther | Non-Final OA | 62d | Pending | Mar 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial